<DOC>
	<DOCNO>NCT01619969</DOCNO>
	<brief_summary>This Randomized , Double-Blind , Placebo-Controlled , Phase 1b Clinical Study Evaluate Activity , Pharmacokinetics , Safety Tolerability Celgosivir Adults Confirmed Dengue Fever .</brief_summary>
	<brief_title>Celgosivir Treatment Against Dengue</brief_title>
	<detailed_description>Patients confirm dengue fever meet inclusion exclusion criterion enrol admitted Investigational Medicine Unit . Patients randomize 1:1 celgosivir placebo . Capsules placebo celgosivir administer 5 day . While hospital , daily clinical exam conduct , blood sample collect viral load , quantitative NS1 , hematology , clinical chemistry , cytokine level pharmacokinetics ( PK ) . Safety assessment conduct . At discharge Study Day 5 , patient ask return Study Days 7 , 10 , 15 blood sample safety assessment .</detailed_description>
	<mesh_term>Fever</mesh_term>
	<mesh_term>Dengue</mesh_term>
	<criteria>Main Fever ≥ 38°C ≤ 48 hr duration . At least two follow criterion indicate probable dengue infection : Live work recent travel dengue endemic area Nausea vomit Presence rash Aches pain , include headache , retroorbital , muscle joint pain Positive NS1 strip assay Main Clinical sign symptom severe dengue Patients certain abnormal laboratory value History presently active intestinal disorder Severe diarrhea Current usage anticoagulant drug Other clinically significant acute illness History severe drug and/or food allergy Exposure investigational agent within 30 day prior study drug administration Clinically significant abnormal physical exam unrelated dengue fever Pregnancy</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>November 2013</verification_date>
</DOC>